Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Depreciation & Amortization (CF) (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $123000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Depreciation & Amortization (CF) rose 720.0% year-over-year to $123000.0, compared with a TTM value of $205000.0 through Dec 2021, up 294.23%, and an annual FY2024 reading of $343000.0, down 21.51% over the prior year.
  • Depreciation & Amortization (CF) was $123000.0 for Q4 2021 at Black Diamond Therapeutics, up from $43000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $123000.0 in Q4 2021 and bottomed at $9000.0 in Q4 2019.
  • Average Depreciation & Amortization (CF) over 3 years is $25333.3, with a median of $13500.0 recorded in 2019.
  • The sharpest move saw Depreciation & Amortization (CF) dropped 16.67% in 2020, then soared 720.0% in 2021.
  • Year by year, Depreciation & Amortization (CF) stood at $9000.0 in 2019, then surged by 66.67% to $15000.0 in 2020, then soared by 720.0% to $123000.0 in 2021.
  • Business Quant data shows Depreciation & Amortization (CF) for BDTX at $123000.0 in Q4 2021, $43000.0 in Q3 2021, and $20000.0 in Q2 2021.